文献速递肿瘤 PET/CT

68Ga-DOTA-E[c(RGDfK)]2 PET显像评估小鼠中SHARPIN调控的整合素活性

68Ga-DOTA-E[c(RGDfK)]2 PET Imaging of SHARPIN-Regulated Integrin Activity in Mice.
PubMed 文献 · J Nucl Med · 2019-03-08

本研究用68Ga-DOTA-E[c(RGDfK)]2 RGD肽PET/CT在野生型与SHARPIN缺陷(Sharpincpdm)小鼠中评估整合素活性,伴或不伴B16-F10-luc黑色素瘤移植。结果显示Sharpincpdm小鼠皮肤和肿瘤的离体摄取显著高于野生型,接种后第10天肿瘤PET摄取也显著更高,且肿瘤血管化增加。提示SHARPIN可能调控肿瘤微环境。

要点

  • Sharpincpdm小鼠皮肤和肿瘤的68Ga-DOTA-E[c(RGDfK)]2离体摄取显著高于野生型。
  • 接种后第10天PET显像显示Sharpincpdm小鼠肿瘤摄取显著高于野生型。
  • Sharpincpdm小鼠肿瘤血管化增加,提示SHARPIN调控肿瘤微环境。

核心结论

  • Sharpincpdm小鼠B16-F10-luc黑色素瘤中整合素活性和血管化增加,可由RGD基PET显像显示。
  • SHARPIN可能对肿瘤微环境具有重要调控作用。

研究设计与样本

  • 使用Sharpin基因自发无效突变的Sharpincpdm小鼠及其野生型同窝小鼠,伴或不伴B16-F10-luc黑色素瘤移植。
  • 采用68Ga-DOTA-E[c(RGDfK)]2环状RGD肽进行在体PET/CT显像和离体测量。
  • 末次PET/CT后取肿瘤冰冻切片行放射自显影、组织学和免疫组化。

主要发现

  • 68Ga-DOTA-E[c(RGDfK)]2在小鼠皮肤和肿瘤的离体摄取在Sharpincpdm小鼠显著高于野生型。
  • B16-F10-luc肿瘤在接种后4天可检测到,两品系间肿瘤体积或血流无差异。
  • 接种后第10天68Ga-DOTA-E[c(RGDfK)]2 PET显像显示移植入Sharpincpdm小鼠的肿瘤摄取显著高于野生型。
  • Sharpincpdm小鼠肿瘤血管化增加。

临床怎么用

  • RGD基PET显像可用于在体评估SHARPIN相关的整合素活性变化。
  • SHARPIN状态可能影响肿瘤微环境中的整合素靶向显像解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Shank-associated RH domain-interacting protein (SHARPIN) is a cytosolic protein that plays a key role in activation of nuclear factor κ-light-chain enhancer of activated B cells and regulation of inflammation. Furthermore, SHARPIN controls integrin-dependent cell adhesion and migration in several normal and malignant cell types, and loss of SHARPIN correlates with increased integrin activity in mice. Arginyl-glycyl-aspartic acid (RGD), a cell adhesion tripeptide motif, is an integrin recognition sequence that facilitates PET imaging of integrin upregulation during tumor angiogenesis. We hypothesized that increased integrin activity due to loss of SHARPIN protein would affect the uptake of αvβ3-selective cyclic, dimeric peptide 68Ga-DOTA-E[c(RGDfK)]2, where E[c(RGDfk)]2 = glutamic acid-[cyclo(arginyl-glycyl-aspartic acid-D-phenylalanine-lysine)], both in several tissue types and in the tumor microenvironment. To test this hypothesis, we used RGD-based in vivo PET imaging to evaluate wild-type (wt) and SHARPIN-deficient mice (Sharpincpdm , where cpdm = chronic proliferative dermatitis in mice) with and without melanoma tumor allografts. Methods:Sharpincpdm mice with spontaneous null mutation in the Sharpin gene and their wt littermates with or without B16-F10-luc melanoma tumors were studied by in vivo imaging and ex vivo measurements with cyclic-RGD peptide 68Ga-DOTA-E[c(RGDfK)]2 After the last 68Ga-DOTA-E[c(RGDfK)]2 peptide PET/CT, tumors were cut into cryosections for autoradiography, histology, and immunohistochemistry. Results: The ex vivo uptake of 68Ga-DOTA-E[c(RGDfK)]2 in the mouse skin and tumor was significantly higher in Sharpincpdm mice than in wt mice. B16-F10-luc tumors were detected 4 d after inoculation, without differences in volume or blood flow between the mouse strains. PET imaging with 68Ga-DOTA-E[c(RGDfK)]2 peptide at day 10 after inoculation revealed significantly higher uptake in the tumors transplanted into Sharpincpdm mice than in wt mice. Furthermore, tumor vascularization was increased in the Sharpincpdm mice. Conclusion:Sharpincpdm mice demonstrated increased integrin activity and vascularization in B16-F10-luc melanoma tumors, as demonstrated by RGD-based in vivo PET imaging. These data indicate that SHARPIN, a protein previously associated with increased cancer growth and metastasis, may also have important regulatory roles in controlling the tumor microenvironment.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Siitonen R, Peuhu E, Autio A, et al. 68Ga-DOTA-E[c(RGDfK)]2 PET Imaging of SHARPIN-Regulated Integrin Activity in Mice. J Nucl Med. 2019. PMID: 30850498. doi:10.2967/jnumed.118.222026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。